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Introduction {#cjp286-sec-0001}
============

The incidence of uveal melanoma (UM) varies between 3 and 8 per million per year in Caucasians, making it the most common primary intraocular malignancy in adults [1](#cjp286-bib-0001){ref-type="ref"}, [2](#cjp286-bib-0002){ref-type="ref"}. Whilst primary tumours are successfully treated using either surgery and/or radiotherapy [3](#cjp286-bib-0003){ref-type="ref"}, up to 50% of patients die from metastatic disease, typically occurring in the liver, for which there is currently no effective systemic therapy [4](#cjp286-bib-0004){ref-type="ref"}, [5](#cjp286-bib-0005){ref-type="ref"}. Stratifying UM patients as at either high or low risk of metastatic spread is critical to ensure patients are managed accordingly: low metastatic risk UM patients can be reassured that they are very unlikely to develop metastases, whilst high metastatic risk UM patients can undergo more intensive liver screening, with the potential of undergoing liver resection surgery at the earliest onset of relapse, and/or enrolment in clinical trials [6](#cjp286-bib-0006){ref-type="ref"}. Prognostication involves the integration of clinical, histological, and genetic features of the tumour, in order to obtain a refined predicted risk [6](#cjp286-bib-0006){ref-type="ref"}, [7](#cjp286-bib-0007){ref-type="ref"}.

UM is characterized by distinct gross chromosomal abnormalities that are associated with patient outcome, the most common being monosomy 3 (M3), which corresponds with a significantly worse prognosis [8](#cjp286-bib-0008){ref-type="ref"}, [9](#cjp286-bib-0009){ref-type="ref"}, [10](#cjp286-bib-0010){ref-type="ref"}, [11](#cjp286-bib-0011){ref-type="ref"}, [12](#cjp286-bib-0012){ref-type="ref"}. M3 is frequently accompanied by polysomy 8q, and increasing copies of 8q significantly correlate with reduced survival, in a dose‐dependent fashion [8](#cjp286-bib-0008){ref-type="ref"}, [10](#cjp286-bib-0010){ref-type="ref"}, [13](#cjp286-bib-0013){ref-type="ref"}, [14](#cjp286-bib-0014){ref-type="ref"}. Further abnormalities described in UM include loss of 1p, which is associated with poor prognosis in the context of M3 [15](#cjp286-bib-0015){ref-type="ref"}, and gains on 6p, which, in the absence of additional chromosomal abnormalities, correspond with a good prognosis [16](#cjp286-bib-0016){ref-type="ref"}, [17](#cjp286-bib-0017){ref-type="ref"}. More recently, mutations occurring in UM have been identified in several genes, including *GNAQ*, *GNA11*, *BAP1*, *SF3B1*, *EIF1AX*, *PLCB4*, and *CYSLTR2* [11](#cjp286-bib-0011){ref-type="ref"}, [18](#cjp286-bib-0018){ref-type="ref"}, [19](#cjp286-bib-0019){ref-type="ref"}, [20](#cjp286-bib-0020){ref-type="ref"}, [21](#cjp286-bib-0021){ref-type="ref"}, [22](#cjp286-bib-0022){ref-type="ref"}. In particular, inactivating *BAP1* mutations are associated with a poor outcome, being present in ∼84% of all UMs that went on to produce metastases [19](#cjp286-bib-0019){ref-type="ref"}, [23](#cjp286-bib-0023){ref-type="ref"}, [24](#cjp286-bib-0024){ref-type="ref"}. *BAP1* mutations similarly correspond with a significantly worse prognosis in renal clear cell carcinoma [25](#cjp286-bib-0025){ref-type="ref"} and cholangiocarcinoma [26](#cjp286-bib-0026){ref-type="ref"}, whilst in mesothelioma *BAP1* inactivation is associated with a good prognosis [27](#cjp286-bib-0027){ref-type="ref"}. Families with members carrying germline mutations in *BAP1* have also been described, with individuals most often affected by mesothelioma, melanomas including UM, and renal cell carcinoma [28](#cjp286-bib-0028){ref-type="ref"}, [29](#cjp286-bib-0029){ref-type="ref"}.

BRCA1‐associated protein 1 (BAP1), encoded by *BAP1* on chromosome 3p21.1, is a nuclear‐localized deubiquitylase (DUB) belonging to the ubiquitin carboxy‐terminal hydrolase family of DUBs [19](#cjp286-bib-0019){ref-type="ref"}, [30](#cjp286-bib-0030){ref-type="ref"}. The 729‐amino acid BAP1 protein includes an N‐terminal catalytic domain, a bipartite C‐terminal nuclear localisation signal (NLS), and binding domains for BRCA1 (Breast Cancer 1), BARD1 (BRCA1‐associated RING domain protein 1), and HCF1 (Host cell factor 1), among others [30](#cjp286-bib-0030){ref-type="ref"}, [31](#cjp286-bib-0031){ref-type="ref"}, [32](#cjp286-bib-0032){ref-type="ref"}. BAP1 has multiple functions, including involvement in DNA damage responses [33](#cjp286-bib-0033){ref-type="ref"}, [34](#cjp286-bib-0034){ref-type="ref"}, [35](#cjp286-bib-0035){ref-type="ref"}, transcriptional activation [35](#cjp286-bib-0035){ref-type="ref"}, chromatin remodelling [36](#cjp286-bib-0036){ref-type="ref"}, and cell cycle regulation [33](#cjp286-bib-0033){ref-type="ref"}, [37](#cjp286-bib-0037){ref-type="ref"}.

Functionally, *BAP1* nonsense or frameshift mutations lead to truncated BAP1 protein with loss of nuclear localisation and/or reduced protein or mRNA stability [23](#cjp286-bib-0023){ref-type="ref"}. This has led to several recent studies assessing the prevalence of nuclear BAP1 protein expression (nBAP1) in UM, and correlating this with clinical outcome [23](#cjp286-bib-0023){ref-type="ref"}, [38](#cjp286-bib-0038){ref-type="ref"}, [39](#cjp286-bib-0039){ref-type="ref"}. Koopmans *et al* [39](#cjp286-bib-0039){ref-type="ref"} and Kalirai *et al* [38](#cjp286-bib-0038){ref-type="ref"} observed loss of nBAP1 protein expression in 43% and 51% of all UM, respectively, which was significantly associated with increased metastatic risk, along with other clinical features linked to poor prognosis. In the latter study, we also noted the presence of differing cytoplasmic staining patterns of BAP1 protein (cBAP1) using immunohistochemistry (IHC). This has also been observed by groups examining BAP1 IHC expression in other cancers [40](#cjp286-bib-0040){ref-type="ref"}, [41](#cjp286-bib-0041){ref-type="ref"}, [42](#cjp286-bib-0042){ref-type="ref"}, and in atypical Spitz tumours [43](#cjp286-bib-0043){ref-type="ref"}. Although the significance of cBAP1 remains unclear, shuttling of BAP1 between the cytoplasm and nucleus has been previously described [44](#cjp286-bib-0044){ref-type="ref"}. Indeed, in cell lines derived from mesothelioma patients, mutant *BAP1* was associated with cytoplasmic sequestration of the protein due to loss of the NLS [45](#cjp286-bib-0045){ref-type="ref"}.

Herein, we report the largest study to date of BAP1 protein expression in UM and provide a comprehensive analysis of nBAP1 and cBAP1, correlating these findings with clinical, genetic, and histopathological tumour characteristics, as well as with outcome.

Materials and methods {#cjp286-sec-0002}
=====================

Ethics {#cjp286-sec-0003}
------

This study conformed to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Approval for the study was obtained from the Health Research Authority (NRES REC ref [16](#cjp286-bib-0016){ref-type="ref"}/SW/0112), and all patients provided informed consent.

Validation studies were carried out on an independent set of samples obtained from The Ohio State University (OSU) and collected according to a separate IRB (OSU2006C0045).

Sample collection {#cjp286-sec-0004}
-----------------

For samples collected in Liverpool, 4 µm sections were cut from formalin‐fixed paraffin‐embedded (FFPE) material obtained from 145 UM patients who were treated by enucleation or local resection at the Liverpool Ocular Oncology Centre (LOOC), Royal Liverpool University Hospital NHS Trust between January 2013 and December 2015. For a further 20 patients, BAP1 IHC had already been undertaken as part of their routine prognostication, and nBAP1 expression data were available from the Ocular Oncology Biobank.

Fourteen samples from OSU were provided as 4 µm sections cut from FFPE blocks.

Immunohistochemistry {#cjp286-sec-0005}
--------------------

The IHC for BAP1was performed as previously described [38](#cjp286-bib-0038){ref-type="ref"} using the Dako PT Link and the Dako EnVision Flex kit on the Autostainer Plus according to the manufacturer\'s standard instructions (Dako, Agilent Technologies LDA UK Limited, Stockport, UK). In brief, a mouse anti‐human BAP1 antibody (0.5 μg ml^−1^; C‐4, Santa Cruz, Insight Biotechnology Ltd, Middlesex, UK) and a rabbit anti‐human GM130 antibody (0.236 μg ml^−1^; EP892Y, Abcam, Cambridgeshire, UK; a marker for the Golgi apparatus) were used. Bound antibody was visualized with either EnVision^TM^ FLEX 3,3′‐diaminobenzidine (DAB+) (Dako) or aminoethylcarbazole (AEC; for highly pigmented tumours) (Vector Labs UK, Peterborough, UK). All sections were counterstained with Mayer\'s haematoxylin (VWR International Ltd, Lutterworth, UK), blued with Scott\'s tap water (Leica Microsystems Ltd, Milton Keynes, UK) and mounted with either Aquatex™ (VWR) or DPX mountant for AEC or DAB+ sections, respectively. Human pancreas tissue was used as a positive control for both BAP1 and GM130. Mouse IgG1 was used as a negative control for BAP1 in tissue sections.

Scoring {#cjp286-sec-0006}
-------

The IHC stained slides were scored by four independent investigators (SEC, HK, NF, ST) using a light microscope (Nikon Eclipse E600). A binary score was used for nBAP1expression; with cases being defined as positive when staining was present in tumour cell nuclei, and negative in its absence. cBAP1 was also defined as 'positive' or 'negative', with the subcellular localisation additionally being recorded as either 'predominantly diffuse', or 'predominantly focal perinuclear'.

DNA extraction and quantification {#cjp286-sec-0007}
---------------------------------

All methods for DNA extraction from FFPE and frozen UM samples and their quantification have been previously described elsewhere [46](#cjp286-bib-0046){ref-type="ref"}, [47](#cjp286-bib-0047){ref-type="ref"}.

Chromosomal copy number analysis {#cjp286-sec-0008}
--------------------------------

The Multiplex Ligation Dependent Probe Amplification (MLPA) and microsatellite (MSA) procedures for the assessment of chromosome 3 copy number alterations were performed as previously described [8](#cjp286-bib-0008){ref-type="ref"}, [48](#cjp286-bib-0048){ref-type="ref"}, [49](#cjp286-bib-0049){ref-type="ref"}. MLPA was performed in all cases yielding \> 100 ng DNA whilst MSA was undertaken for samples with lower DNA yield. For samples obtained from OSU, chromosome 3 status was assessed by microsatellite‐based genotyping [46](#cjp286-bib-0046){ref-type="ref"}.

Mutation analysis {#cjp286-sec-0009}
-----------------

We hypothesized that the phenomenon of 'focal perinuclear' cBAP1 may be due to distinct *BAP1* mutations resulting in mis‐localisation. To study this, we sequenced all *BAP1* exons in 9 UM cases that were nBAP1 positive as well as 17 nBAP1 negative UM (7 cBAP1 diffuse, 9 cBAP1 focal perinuclear, and 1 cBAP1 negative). These cases were chosen because they demonstrated a clear immunophenotype for nBAP1 and also provided good quality DNA. Targeted sequencing of *BAP1* in these cases was performed by the Rotterdam Ocular Melanoma Study group, using the Ion Torrent Personal Genome Machine or by direct Sanger sequencing at OSU [50](#cjp286-bib-0050){ref-type="ref"}. SNPs were called using Torrent Suite Software V4.4.3 (Thermofisher Scientific Ltd, Hemel Hempstead, UK) and variants were identified and annotated using SnpEff version 3.2a.

A second cohort of 14 UM samples had previously undergone direct sequencing for *BAP1* alterations at OSU. Results were read by aligning with the reference sequence provided by Genbank accession number NM_004656.2, utilizing the Sequencher software (Version 4.8, Gene Codes Corp, Ann Arbor, MI, USA).

Statistical analysis {#cjp286-sec-0010}
--------------------

Multivariate analysis of risk factors associated with development of metastatic disease was undertaken using the Cox proportional hazards model for all covariates with *p* ≤ 0.10 by univariate analysis. Survival time (months) was calculated from the date of first diagnosis until death, or study closure on 28 February 2017. All analyses were carried out using SPSS Statistics v.24 (IBM).

Results {#cjp286-sec-0011}
=======

Patient demographics and tumour sample details {#cjp286-sec-0012}
----------------------------------------------

Initial analyses relate to 165 UM patients treated with surgical excision at the LOOC between January 2013 and December 2015 (supplementary material, Table S1); 154 enucleation, 9 local resection and 2 endoresections. In 29 cases, the surgical excision analysed was not the primary treatment, but instead was performed when tumour recurrence or local complications had followed first treatment. The median time from first presentation to surgical excision for these cases was 33.5 months (range 1--570).

Of the 165 patients, 96 were males and 69 females, with a median age of 63 years at primary management (range, 20--88 years) and a median follow‐up of 31.3 months (range, 5.7--348.5 months). At the time of study closure (28 February 2017), 133/165 (81%) UM patients were alive; 25/165 (15%) patients had died from metastatic disease, and 7/165 (4%) had died from other causes. The median largest basal diameter (LBD) was 14.4 mm (range, 3.3--23.6 mm), with a median tumour height of 8.3 mm (range, 0.1--18.5 mm). Epithelioid cells were present in 104/165 (63%) UM, 61/165 (37%) tumours involved the ciliary body, and 20/165 (12%) had extraocular extension. Further histomorphological characteristics of the tumours are summarized in supplementary material, Table S1.

As determined by either MLPA (153 cases) or MSA (12 cases), 103/165 (62%) UM were classified as M3, 48/165 (29%) UM as disomy 3 (D3), and one UM(1%) was isodisomy 3; in all subsequent statistical analyses, this was classified with the M3 cases (supplementary material, Table S2). Thirteen UM (8%) could not be classified as either M3 or D3 due to poor quality DNA.

Nuclear BAP1 protein localisation was observed in 77/165 (45.5%) UM, and absent in 88/165 (54.5%) (Figure [1](#cjp286-fig-0001){ref-type="fig"} and supplementary material, Tables S1 and S2). There was no significant heterogeneity of nBAP1 protein expression amongst the tumour cells, such that the cases were either clearly nBAP1 positive or negative. Glial cells within the optic nerve as well as within the plexiform cells of the neurological retina were used as intrinsic positive controls for nBAP1 expression (Figure [1](#cjp286-fig-0001){ref-type="fig"}A). Pancreas sections served as external controls (Figure [1](#cjp286-fig-0001){ref-type="fig"}B). Non‐neoplastic uveal melanocytes were positive for nBAP1 expression (Figure [1](#cjp286-fig-0001){ref-type="fig"}C). No positive staining was observed in sections incubated with mouse IgG1 instead of the BAP1 antibody.

![Prognostic value of nuclear BAP1 protein expression. (A--C) Representative images of nuclear BAP1 protein (nBAP1) expression in primary UM (x10 magnification); insets show nBAP1 at x40 magnification. (A) nBAP1 negative tumour with focal perinuclear cBAP1. Intrinsic nuclear positivity is present in the adjacent neural retinal tissue (bottom inset). (B) Positive (left) and negative (right) nBAP1 staining in pancreas control sections. (C) nBAP1 staining in non‐neoplastic uveal melanocytes. (D) nBAP1 positive UM (left) and a nBAP1 negative UM (right). (E, F) Kaplan‐Meier survival curves and tables for primary UM in the Liverpool cohort stratified according to: (E) nBAP1 protein expression (*n* = 165; Log Rank, *p* \< 0.001) (nBAP1 protein expression was scored as positive or negative); or (F) chromosome 3 status (*n* = 152; Log Rank, *p* = 0.001), where only cases with a discernible normal or loss of chromosome 3 were included. Number of events indicates the number of deaths due to metastatic melanoma. Log‐rank tests were used to compare survival across groups. BAP1 positivity was detected using a brown chromogen in (A), (B), and (D) and a red chromogen in (C).](CJP2-4-26-g001){#cjp286-fig-0001}

As expected, the majority of M3 (84/104, 81%) were nBAP1 negative; however, 20/104 (19%) demonstrated nBAP1positivity (Figure [2](#cjp286-fig-0002){ref-type="fig"}A). Of the 48 D3 UM, the majority (46/48, 96%) were nBAP1 positive. Two D3 UM were nBAP1 negative and were subsequently re‐tested by MSA to rule out isodisomy 3, which is not detectable by MLPA; both had a D3 classification by MSA. Of interest, 90 UM demonstrated 8q gains with 61/90 (68%) being BAP1 negative (supplementary material, Table S2). Furthermore, of the 25 UM patients who died from metastatic UM, 22 (88%) had nBAP1 negative primary tumours (supplementary material, Table S1). Of the three nBAP1 positive cases in this group, the chromosome 3 status was M3 in one, D3 in one, and unclassifiable in the remaining case.

![nBAP1 status contributes additional prognostic information in M3‐UM patients. (A) Pie chart summarizing the breakdown of nBAP1 staining and chromosome 3 status in the Liverpool cohort of patients, *n* = 165. (B, C) Kaplan‐Meier survival curves and tables estimating disease‐free survival in UM patients stratified by: (B) nBAP1+ve/--ve status in monosomy 3 (M3) patients, *n* = 104 and (C) nBAP1+ve/--ve status in disomy 3 (D3) patients, *n* = 48. Number of events indicates the number of deaths due to metastatic melanoma. Log‐rank tests were used to compare survival across groups.](CJP2-4-26-g002){#cjp286-fig-0002}

Survival {#cjp286-sec-0013}
--------

Kaplan‐Meier survival curves and tables were examined for all primary UMs stratified according to nBAP1 protein expression or chromosome 3 status. Both UMs negative for nBAP1 (Log Rank, *p* \< 0.001) and M3 UMs (Log rank, *p* = 0.001) were significantly associated with a reduced survival time (Figure [1](#cjp286-fig-0001){ref-type="fig"}D,E). The cases were further subdivided according to their chromosome 3 status (Figure [2](#cjp286-fig-0002){ref-type="fig"}A--C). Strikingly, M3/nBAP1 positive UM had a significantly better prognosis than M3/nBAP1 negative tumours (Log rank, *p* = 0.014), which was in fact similar to that of patients with D3/nBAP1 positive UM (Figure [2](#cjp286-fig-0002){ref-type="fig"}B).

Univariate and multivariate analysis {#cjp286-sec-0014}
------------------------------------

Univariate analysis identified the following factors as significantly associated with survival time (supplementary material, Table S3): nBAP1 protein expression, *p* ≤ 0.001 (HR 0.173; 95% CI 0.067--0.450); age at primary management, *p* = 0.005 (HR 1.046; 95% CI 1.014--1.080); presence of closed connective loops, *p* = 0.003 (HR 3.596; 95% CI 1.541--8.389); mitotic count per 40 high power field, *p* = 0.016 (HR 1.029; 95% CI 1.005--1.054); epithelioid cell morphology, *p* = 0.014 (HR 3.059; 95% CI 1.257--7.443); tumour height, *p* = 0.002 (HR 1.169; 95% CI 1.058--1.292); LBD, *p* = 0.006 (HR 1.142; 95% CI 1.039--1.255); and chromosome 3 loss, *p* = 0.036 (HR 0.482; 95% CI 0.243--0.955). Multivariate analysis demonstrated only nBAP1 protein expression as an independent factor significantly associated with survival, *p* = 0.002 (HR 0.211; 95% CI 0.079--0.562) in this cohort (Table [1](#cjp286-tbl-0001){ref-type="table-wrap"}).

###### 

Multivariate analysis of risk factors associated with metastasis in uveal melanoma

  Variable   Significance   Hazard ratio (HR)   95% CI for HR   
  ---------- -------------- ------------------- --------------- -------
  nBAP1      **0.006**      0.212               0.070           0.645
  AgePM      0.071          1.030               0.997           1.064
  Chr3       0.974          1.011               0.540           1.892

AgePM, age at primary management; Chr3, Chromosome 3; nBAP1, nuclear BAP1; CI, confidence interval.

Cytoplasmic BAP1 protein expression {#cjp286-sec-0015}
-----------------------------------

We next examined the 145 UM stained by the Liverpool Ocular Oncology Research Group for cytoplasmic expression of BAP1. Eighteen of these were excluded from the analysis due to high levels of pigmentation, which made the cBAP1 localisation difficult to distinguish, so 127 UM were ultimately included in the analysis. cBAP1 staining was not observed in the glial cells of the optic nerve or the plexiform cells of the neurological retina, which served as intrinsic positive controls, nor was it detected in mouse IgG1 incubated negative control sections. cBAP1 localisation was recorded as 'predominantly diffuse', 'predominantly focal perinuclear', or negative. Of the127 UM examined, 68 (53.5%) were nBAP1 positive, whilst 59 (46.5%) were nBAP1 negative (Figure [3](#cjp286-fig-0003){ref-type="fig"}). nBAP1 positive UM demonstrated 'predominantly diffuse' cytoplasmic staining in 53/68 (77.9%) cases examined; the remaining 15/68 (22.1%) showed no detectable cBAP1 expression, with none showing the focal perinuclear phenotype.

![Cytoplasmic BAP1 exhibits differential localisation in UM. (A) Images showing either diffuse (left; DAB) or focal perinuclear (centre; DAB and right; AEC) localisation of cytoplasmic BAP1 (cBAP1) in three nBAP1 negative UM (main image and insets are at ×10 and ×40 magnification, respectively; scale bars 200 μm). (B) Pie charts summarizing the breakdown of nBAP1 expression in the 127 UMs studied (left) and cBAP1 expression in the 59 nBAP1 negative cases (right). (C) Kaplan‐Meier survival curve for 54 nBAP1 negative UM patients stratified by focal perinuclear and diffuse cBAP1 staining patterns. The difference in survival was not significant (Log rank; *p* = 0.925). (D) Images showing similar localisation of focal perinuclear cBAP1 with the cis Golgi marker GM130 in 3 μm serial sections of two UM cases (I and II) (scale bars 60 μm).](CJP2-4-26-g003){#cjp286-fig-0003}

Of particular interest were the nBAP1 negative UMs that exhibited a distinct 'focal perinuclear' cBAP1 localisation in 18/59 (31%) cases (Figure [3](#cjp286-fig-0003){ref-type="fig"}A,B). 'Predominantly diffuse' cBAP1 was noted in 36/59 (61%) cases and there was no detectable cBAP1 in 5/59 (8%). Overall, these results suggest that complete loss of BAP1protein expression is uncommon in UM.

This 'focal perinuclear' cBAP1 phenotype did not significantly affect overall survival relative to predominantly diffuse or negative cBAP1 in the nBAP1 negative UM (Log rank, *p* = 0.925; Figure [3](#cjp286-fig-0003){ref-type="fig"}C), nor did it correlate significantly with other clinical parameters or gross chromosomal abnormalities.

To take into account possible artefacts created by fixation and processing, we further examined our cBAP1 findings using an external independent cohort of UM (*n* = 14) with available *BAP1* mutational status from the pathology archives of OSU. In keeping with the frequency of nBAP1 loss by IHC in the Liverpool cohort, 7/16 (44%) UM were nBAP1 positive and 9/16 (56%) were nBAP1 negative. All nBAP1 positive UM in this cohort had 'predominantly diffuse' cBAP1. nBAP1 negative UM showed 'focal perinuclear' cBAP1 localisation in 3/9 (33%) cases with6/9 (66%) showing 'predominantly diffuse' cBAP1 staining, again consistent with our findings above.

Golgi localisation of cytoplasmic BAP1 {#cjp286-sec-0016}
--------------------------------------

Our results showing "focal perinuclear" cBAP1 protein accumulation in nBAP1 negative (but not nBAP1 positive) UM suggests that this reflects aberrant BAP1 processing and/or trafficking. We noted that the perinuclear distribution was similar to the location of the Golgi apparatus: to assess whether the cBAP1 may indeed be accumulating in the Golgi apparatus, adjacent serial UM sections were stained for BAP1 and the cis Golgi marker, GM130. Interestingly, the GM130 and cBAP1 staining profiles were very similar, indicating that BAP1 is localized near, or possibly within, the cis Golgi in these cells (Figure [3](#cjp286-fig-0003){ref-type="fig"}D).

BAP1 mutation analysis {#cjp286-sec-0017}
----------------------

As expected, all 9 nBAP1 positive UM had wild‐type *BAP1*. Of the 17 nBAP1 negative cases examined, 3/7 cBAP1 diffuse UM were wild‐type for *BAP1*and 1/7 harboured a splice acceptor mutation prior to exon 2, causing loss‐of‐function, while 3/7 had truncating, loss‐of‐function *BAP1* mutations (Figure [4](#cjp286-fig-0004){ref-type="fig"} and supplementary material, Table S4). In contrast, 7/9 cBAP1 'focal perinuclear' UM harboured loss‐of‐function *BAP1* mutations. In one case, exon 17 was flanked by an intron variant and a 3′ UTR variant, the pathogenic significance of which is unclear. The remaining case was wild‐type for *BAP1*. In the independent OSU cohort, 6/9 nBAP1 negative UM harboured a *BAP1* mutation, and 1/9 had a benign variant rs149499021. In the nBAP1 positive UM, 4/5 showed no mutation with only one case having the benign variant rs149499021 \[40\]. Of the three cases showing 'focal perinuclear' cBAP1, two had INDELs and one had a benign variant (supplementary material, Table S5).

![UMs with focal perinuclear cBAP1 tend to harbour loss‐of‐function *BAP1* mutations. (A) Schematic showing the location of mutations within the *BAP1* gene. 5′ and 3′ UTRs are depicted in red. One UM had two mutations flanking exon 17 (+); (B) location of the mutations shown in (A) mapped to the BAP1 protein (UCH, ubiquitin carboxy‐terminal hydrolase domain; BARD1, BARD1‐binding domain; HBM, HCF1‐binding domain; BRCA1, BRCA1‐binding domain; ULD, UCH‐37‐like domain; NLS, nuclear localisation signal. The location of cysteine, histidine, and aspartic acid residues of the catalytic triad are shown in the catalytic domain. (C) Histogram showing the distribution of mutation types for the nBAP1 positive, nBAP1 negative (cBAP1 diffuse), nBAP1 negative (cBAP1 focal perinuclear), and nBAP1 negative (cBAP1 negative) UMs.](CJP2-4-26-g004){#cjp286-fig-0004}

Overall, we identified 6/25 (24%) cases in both cohorts analysed that were nBAP1 negative but did not harbour a *BAP1* mutation.

Discussion {#cjp286-sec-0018}
==========

This is the largest study to date examining BAP1 protein expression in UM by IHC. Where feasible, we have also correlated the nuclear and cytoplasmic staining patterns of BAP1with clinical features, including outcome, as well as with BAP1 sequencing data. In this study, we have demonstrated that nBAP1 protein expression is lost in 54% of UM, and that nBAP1 is a significant independent prognostic indicator, which identifies a subset of M3 UM with nBAP1 expression that have prolonged survival as compared with M3 UM that have lost nBAP1 expression. We provide evidence to suggest that the subcellular localisation of cBAP1 in nBAP1‐negative UM is associated with the presence of *BAP1* mutations. That is, UM with 'focal perinuclear' cBAP1 tended to carry loss‐of‐function *BAP1* mutations compared to UM with diffuse cytoplasmic BAP1.

Nuclear BAP1 findings {#cjp286-sec-0019}
---------------------

BAP1 IHC is currently routinely performed only on surgically resected specimens in our centre. In the current study, this included tumours resected because of size, location, recurrence, secondary complications, and patient preference. Whilst we recognize that there may be a potential bias as compared with an analysis of all UM, the frequency of nBAP1 negativity in this study (54%) is consistent with that reported in the literature (43--58%) [23](#cjp286-bib-0023){ref-type="ref"}, [38](#cjp286-bib-0038){ref-type="ref"}, [39](#cjp286-bib-0039){ref-type="ref"}. Similar to these other reports, we demonstrated a correlation between loss of nBAP1 expression and poor prognostic parameters known to be associated with 'high risk' UM -- i.e. increasing age at primary management; ciliary body involvement; increasing tumour LBD; large tumour height; epithelioid cell morphology; PAS‐positive connective tissue loops; and loss of chromosome 3 \[6\].

Previous studies have indicated that there is a strong association between the absence of nBAP1 protein expression and mutations in *BAP1* \[23,39\]. For example, Van de Nes *et al* demonstrated in a cohort of 66 UM that 33/37 (89%) M3 UM had a *BAP1* mutation together with an absence of nBAP1 protein expression [23](#cjp286-bib-0023){ref-type="ref"}. A similar proportion was reported by Koopmans *et al* in their study of 74 UM, with 88% of the M3 UM harbouring a *BAP1* mutation together with loss of nuclear protein expression [39](#cjp286-bib-0039){ref-type="ref"}. In our current study of 26 nBAP1 negative UM, 20 (77%) harboured mutations in *BAP1*, which is similar to the previous reports detailed above.

Of particular interest in our current study was the identification of a subset of M3 UM (20/104; 19%) that showed nBAP1 positivity, correlating with a significantly increased survival time as compared with the M3/nBAP1‐negative UM (*p* = 0.014) (Figure [2](#cjp286-fig-0002){ref-type="fig"}B). Whilst the follow‐up is relatively short for these 20 individuals, the data support our previous description of a patient with nBAP1 positive liver metastases who was still alive after more than 10 years post enucleation [51](#cjp286-bib-0051){ref-type="ref"}. More recently, BAP1 IHC performed at our centre showed nBAP1 positivity in metastatic UM cells within the liver of a patient who is alive 37 years after diagnosis of the primary UM. This suggests that two distinct subgroups exist within UM with loss of chromosome 3: those M3 UM with a loss of *BAP1* function, and those M3 UM with a retained functional copy of *BAP1*. Indeed, three M3/nBAP1 positive cases were analysed for *BAP1* mutations and found to be wild type. These data were also reflected in the multivariate analysis where nBAP1 was found to be the only independent variable significantly associated with increased risk of developing metastatic disease. Overall, our data strongly suggest that bi‐allelic inactivation of *BAP1* is required to influence prognosis; on this basis, we would predict that the loss of other genes on chromosome 3 may have little or no additional effect on prognosis in this group.

In a small number of cases, however, BAP1 loss is clearly not the metastatic driver. For example, 3/26 (12%) UM patients in our study who developed metastatic disease were found to have nBAP1 positive primary tumours. Two of these patients also had unfavourable clinical and histological characteristics, which would have placed them in the 'high risk' category for developing metastatic disease, irrespective of the tumour\'s nBAP1 status. These other factors included epithelioid cell morphology, high mitotic count, large tumour size, 8q gain, ciliary body involvement, and extraocular growth [3](#cjp286-bib-0003){ref-type="ref"}.The remaining case, however, is unusual in that it was D3 with clinical and histological features of a low metastatic risk tumour. Previous studies have suggested that D3 UM with a mutation in splicing Factor 3B Subunit 1A (*SF3B1*) have an increased risk of developing metastases [52](#cjp286-bib-0052){ref-type="ref"}. Further studies are necessary to determine whether such a mutation is present in this particular case.

Other unusual cases in our patient cohort included three nBAP1 negative UM with no corresponding loss of chromosome 3. Chromosome 3 copy number for all three cases was re‐examined by MSA, which is able to detect isodisomy, i.e. loss of heterozygosity due to acquisition of both copies of the chromosome from the same parent. Only one of the three cases showed isodisomy 3 by MSA. The remaining two cases were tested for *BAP1* mutations, but were found to be wild type, suggesting alternative mechanisms of nBAP1 loss.

Cytoplasmic *BAP1* expression findings {#cjp286-sec-0020}
--------------------------------------

Our study is the first to characterize cBAP1 in UM by IHC, and the first to investigate the link between cBAP1 genotype and phenotype. Our observation of 'focal perinuclear' cBAP1 localisation is consistent with a study by Gammon *et al* [43](#cjp286-bib-0043){ref-type="ref"}, who observed 'clumped perinuclear' cBAP1 in 53% of nBAP1 negative sporadic epithelioid Spitz tumours. They further hypothesized that 'focal perinuclear' cBAP1 may be trapped in the Golgi zone, which our experimental findings using the cis Golgi marker, GM130, would support. It should also be mentioned that mouse acites Golgi reactive (MAG) antibodies have been described in some monoclonal antibody preparations, resulting in non‐specific cross reactivity with blood group A1 antigens present in patient tissues [53](#cjp286-bib-0053){ref-type="ref"}, [54](#cjp286-bib-0054){ref-type="ref"}, [55](#cjp286-bib-0055){ref-type="ref"}. It is unlikely, given the prevalence of blood group A1 in the population (∼35% individuals), however, that MAG antibodies are responsible for the small percentage of cases (11%) with 'focal perinuclear' positivity observed in our study. Moreover, a recent study by Bononi *et al* also described cBAP1 localisation to the endoplasmic reticulum where it regulates Ca^2+^ release to promote apoptosis [56](#cjp286-bib-0056){ref-type="ref"}. In fibroblasts and mesothelial cells derived from individuals with a heterozygous germline *BAP1^+/--^* mutation, they demonstrated a reduced Ca^2+^ flux that reduced the ability of*BAP1^+/--^* mutant cells to undergo apoptosis following DNA damage. Taken together, these results suggest that there is indeed a functional role of cBAP1 in particular cancer types requiring further study.

The preponderance of UM with 'focal perinuclear' cBAP1 that harbour truncating mutations is of interest as one might assume that mutations causing premature stop codons would trigger nonsense‐mediated decay of the aberrant transcript, so that incorrect protein is not produced. One possibility, however, is that the UM cells bypass the premature stop codon by using alternative splice sites [57](#cjp286-bib-0057){ref-type="ref"} and/or read‐through translation [58](#cjp286-bib-0058){ref-type="ref"} to generate misfolded proteins that are not able to exit the Golgi following processing. Consistent with this, Jensen *et al*, who first described BAP1, identified a number of putative N‐linked BAP1 glycosylation sites, suggesting that BAP1 may traverse the Golgi during maturation [30](#cjp286-bib-0030){ref-type="ref"}. Bhattacharya and colleagues [59](#cjp286-bib-0059){ref-type="ref"} suggested an alternative mechanism for the observation of 'focal perinuclear' cBAP1 in the form of cBAP1 aggregates promoted by *BAP1* mutations, which expose hydrophobic regions of the protein, leading to beta amyloid aggregation. However, their study proposed that specific mis‐sense mutations in the catalytic domain were responsible for the observed aggregation, whereas our sequencing results suggest that sporadic truncating mutations throughout *BAP1* can induce the 'focal perinuclear' phenotype. Further studies of the molecular biology of the focal perinuclear phenotype will be warranted.

Our results identifying six nBAP1 negative UM with wild‐type *BAP1* is consistent with reports by van de Nes *et al* [23](#cjp286-bib-0023){ref-type="ref"} and Royer‐Bertrand *et al* [12](#cjp286-bib-0012){ref-type="ref"}, in which five and three cases, respectively, with this phenotype/genotype were described. It is tempting to speculate that a post‐translational mechanism, perhaps in the form of UBE2O upregulation, could be responsible for the aberrant cytoplasmic localisation of BAP1 in these cases. The putative E2/E3 hybrid ubiquitin ligase, UBE2O, has been reported to mediate cytoplasmic translocation of BAP1 by multi‐monoubiquitylation of the NLS. Auto‐deubiquitylation by BAP1 antagonizes the activity of UBE2O, promoting its nuclear retention [44](#cjp286-bib-0044){ref-type="ref"}.

Finally, whilst our study found no link between cBAP1 expression and overall survival (Log rank; *p* = 0.33), it is of interest that Zhang *et al* [60](#cjp286-bib-0060){ref-type="ref"} found that high expression of cBAP1 in gliomas was significantly associated with worse overall survival compared to low cBAP1 expression, although there was no mention of any specific localisation of the cBAP1 in this study. A larger cohort of UM with a longer follow‐up period is required to ascertain whether a dose‐dependent effect of cBAP1 is of clinical relevance.

In summary, we have demonstrated the importance of nBAP1 protein expression as an independent marker of prognosis in patients with UM and that identifies a subpopulation of M3 tumours with favourable survival times compared to their nBAP1‐negative counterparts. We also report that exclusion of BAP1 protein from the nucleus is most commonly associated with retention of cBAP1. The molecular mechanisms underpinning 'focal perinuclear' cBAP1 remain unknown, and warrant further study.
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